Neoadjuvant immunotherapy with chitosan and interleukin-12 to control breast cancer metastasis

References

• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64:9-29; PMID:24399786; http://dx.doi.org/10.3322/caac.21208
   PubMed Web of Science ®Google Scholar
• NCDB Analytic Cases: Disease site by American Joint Committee on Cancer Stage. NCDB Benchmark Reports; September 13, 2013. Available from: https://cromwell.facs.org/BMarks/BMCmp/ver10/Docs/. Accessed June 1, 2014
   Google Scholar
• (EBCTCG) EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-717; PMID:15894097; http://dx.doi.org/10.1016/S0140-6736(05)66544-0
   PubMed Web of Science ®Google Scholar
• Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, Buzdar AU, Booser DJ, Valero V, Bondy M et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 2008; 100:1179-83; PMID:18695137; http://dx.doi.org/10.1093/jnci/djn233
   PubMedGoogle Scholar
• Dong C, Chen L. Second malignancies after breast cancer: The impact of adjuvant therapy. Mol Clin Oncol 2014; 2:331-6; PMID:24772296
   PubMedGoogle Scholar
• Hanna MG. Immunotherapy with autologous tumor cell vaccines for treatment of occult disease in early stage colon cancer. Hum Vaccin Immunother 2012; 8:1156-60; PMID:22854664; http://dx.doi.org/10.4161/hv.20740
   PubMed Web of Science ®Google Scholar
• Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there yet? Immunol Rev 2011; 239:27-44; PMID:21198663; http://dx.doi.org/10.1111/j.1600-065X.2010.00979.x
   PubMed Web of Science ®Google Scholar
• Lu W, Su J, Kim LS, Bucana CD, Donawho C, He J, Fidler IJ, Dong Z. Active specific immunotherapy against occult brain metastasis. Cancer Res 2003; 63:1345-50; PMID:12649197
   PubMed Web of Science ®Google Scholar
• Horinaga M, Harsch KM, Fukuyama R, Heston W, Larchian W. Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model. Urology 2005; 66:461-6; PMID:16040105; http://dx.doi.org/10.1016/j.urology.2005.03.052
   PubMed Web of Science ®Google Scholar
• Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13:155-68; PMID:11900991; http://dx.doi.org/10.1016/S1359-6101(01)00032-6
   PubMed Web of Science ®Google Scholar
• Boggio K, Nicoletti G, Di Carlo E, Cavallo F, Landuzzi L, Melani C, Giovarelli M, Rossi I, Nanni P, De Giovanni C et al. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2neu transgenic mice. J Exp Med 1998; 188:589-96; PMID:9687535; http://dx.doi.org/10.1084/jem.188.3.589
   PubMed Web of Science ®Google Scholar
• Pan WY, Lo CH, Chen CC, Wu PY, Roffler SR, Shyue SK, Tao MH. Cancer immunotherapy using a membrane-bound interleukin-12 with B7-1 transmembrane and cytoplasmic domains. Mol Ther 2012; 20:927-37; PMID:22334018; http://dx.doi.org/10.1038/mt.2012.10
   PubMed Web of Science ®Google Scholar
• Rakhmilevich AL, Janssen K, Hao Z, Sondel PM, Yang NS. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism. Cancer Gene Ther 2000; 7:826-38; PMID:10880012; http://dx.doi.org/10.1038/sj.cgt.7700176
   PubMed Web of Science ®Google Scholar
• Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP, Vogelzang NJ, Ryan JL. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997; 90:2541-8; PMID:9326219
   PubMed Web of Science ®Google Scholar
• Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008; 222:357-68; PMID:18364014; http://dx.doi.org/10.1111/j.1600-065X.2008.00604.x
   PubMed Web of Science ®Google Scholar
• Chinnasamy D, Yu Z, Kerkar SP, Zhang L, Morgan RA, Restifo NP, Rosenberg SA. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin Cancer Res 2012; 18:1672-83; PMID:22291136; http://dx.doi.org/10.1158/1078-0432.CCR-11-3050
   PubMed Web of Science ®Google Scholar
• Simpson-Abelson MR, Purohit VS, Pang WM, Iyer V, Odunsi K, Demmy TL, Yokota SJ, Loyall JL, Kelleher RJ Jr, Balu-Iyer S et al. IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments. Clin Immunol 2009; 132:71-82; PMID:19395317; http://dx.doi.org/10.1016/j.clim.2009.03.516
   PubMed Web of Science ®Google Scholar
• Salem ML, Gillanders WE, Kadima AN, El-Naggar S, Rubinstein MP, Demcheva M, Vournakis JN, Cole DJ. Review: novel nonviral delivery approaches for interleukin-12 protein and gene systems: curbing toxicity and enhancing adjuvant activity. J Interferon Cytokine Res 2006; 26:593-608; PMID:16978064; http://dx.doi.org/10.1089/jir.2006.26.593
   PubMed Web of Science ®Google Scholar
• Sangro B, Melero I, Qian C, Prieto J. Gene therapy of cancer based on interleukin 12. Curr Gene Ther 2005; 5:573-81; PMID:16457647; http://dx.doi.org/10.2174/156652305774964712
   PubMed Web of Science ®Google Scholar
• Cemazar M, Jarm T, Sersa G. Cancer electrogene therapy with interleukin-12. Curr Gene Ther 2010; 10:300-11; PMID:20560875; http://dx.doi.org/10.2174/156652310791823425
   PubMed Web of Science ®Google Scholar
• Hallaj-Nezhadi S, Lotfipour F, Dass C. Nanoparticle-mediated interleukin-12 cancer gene therapy. J Pharm Pharm Sci: Pub Can Soc Pharm Sci, Soc Can Des Sci Pharm 2010; 13:472-85; PMID:21092717
   PubMed Web of Science ®Google Scholar
• Anwer K, Barnes MN, Fewell J, Lewis DH, Alvarez RD. Phase-I clinical trial of IL-12 plasmidlipopolymer complexes for the treatment of recurrent ovarian cancer. Gene therapy 2010; 17:360-9; PMID:20033066; http://dx.doi.org/10.1038/gt.2009.159
   PubMed Web of Science ®Google Scholar
• Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol: Off J Am Soc Clin Oncol 2008; 26:5896-903; PMID:19029422; http://dx.doi.org/10.1200/JCO.2007.13.9048
   PubMed Web of Science ®Google Scholar
• Egilmez NK, Jong YS, Sabel MS, Jacob JS, Mathiowitz E, Bankert RB. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res 2000; 60:3832-7; PMID:10919657
   PubMed Web of Science ®Google Scholar
• Egilmez NK, Kilinc MO, Gu T, Conway TF. Controlled-release particulate cytokine adjuvants for cancer therapy. Endocr Metab Immune Disord Drug Targets 2007; 7:266-70; PMID:18220947; http://dx.doi.org/10.2174/187153007782794335
   PubMedGoogle Scholar
• Zaharoff DA, Hance KW, Rogers CJ, Schlom J, Greiner JW. Intratumoral immunotherapy of established solid tumors with chitosanIL-12. J Immunother 2010; 33:697-705; PMID:20664357; http://dx.doi.org/10.1097/CJI.0b013e3181eb826d
   PubMed Web of Science ®Google Scholar
• Zaharoff DA, Hoffman BS, Hooper HB, Benjamin CJ, Khurana KK, Hance KW, Rogers CJ, Pinto PA, Schlom J, Greiner JW. Intravesical immunotherapy of superficial bladder cancer with chitosaninterleukin-12. Cancer Res 2009; 69:6192-9; PMID:19638573; http://dx.doi.org/10.1158/0008-5472.CAN-09-1114
   PubMed Web of Science ®Google Scholar
• Pogoda K, Niwińska A, Murawska M, Pieńkowski T. Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. Med Oncol 2013; 30:388; PMID:23292831; http://dx.doi.org/10.1007/s12032-012-0388-4
   PubMed Web of Science ®Google Scholar
• Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992; 52:1399-405; PMID:1540948
   PubMed Web of Science ®Google Scholar
• Pulaski BA, Ostrand-Rosenberg S. Mouse 4T1 breast tumor model. Curr Protoc Immunol 2001; 39:20.2:20.2.1–20.2.16; PMID:18432775; http://dx.doi.org/10.1002/0471142735.im2002s39
   PubMedGoogle Scholar
• Guiducci C, Di Carlo E, Parenza M, Hitt M, Giovarelli M, Musiani P, Colombo MP. Intralesional injection of adenovirus encoding CC chemokine ligand 16 inhibits mammary tumor growth and prevents metastatic-induced death after surgical removal of the treated primary tumor. J Immunol 2004; 172:4026-36; PMID:15034014; http://dx.doi.org/10.4049/jimmunol.172.7.4026
   PubMed Web of Science ®Google Scholar
• Gil M, Seshadri M, Komorowski MP, Abrams SI, Kozbor D. Targeting CXCL12CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases. Proc Natl Acad Sci U S A 2013; 110:E1291-300; PMID:23509246; http://dx.doi.org/10.1073/pnas.1220580110
   PubMed Web of Science ®Google Scholar
• Sabel MS, Su G, Griffith KA, Chang AE. Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-alpha in a model of metastatic breast cancer. Breast Cancer Res Treat 2010; 122:325-36; PMID:19802695; http://dx.doi.org/10.1007/s10549-009-0570-3
   PubMed Web of Science ®Google Scholar
• Sabel MS, Hill H, Jong YS, Mathiowitz E, Bankert RB, Egilmez NK. Neoadjuvant therapy with interleukin-12-loaded polylactic acid microspheres reduces local recurrence and distant metastases. Surgery 2001; 130:470-8; PMID:11562672; http://dx.doi.org/10.1067/msy.2001.115839
   PubMed Web of Science ®Google Scholar
• Kilinc MO, Aulakh KS, Nair RE, Jones SA, Alard P, Kosiewicz MM, Egilmez NK. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effectormemory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors. J Immunol 2006; 177:6962-73; PMID:17082611; http://dx.doi.org/10.4049/jimmunol.177.10.6962
   PubMed Web of Science ®Google Scholar
• Kilinc MO, Gu T, Harden JL, Virtuoso LP, Egilmez NK. Central role of tumor-associated CD8+ T effectormemory cells in restoring systemic antitumor immunity. J Immunol 2009; 182:4217-25; PMID:19299720; http://dx.doi.org/10.4049/jimmunol.0802793
   PubMed Web of Science ®Google Scholar
• Kilinc MO, Rowswell-Turner RB, Gu T, Virtuoso LP, Egilmez NK. Activated CD8 +T-effectormemory cells eliminate CD4+ CD25+ Foxp3+ T-suppressor cells from tumors via FasL mediated apoptosis. J Immunol 2009; 183:7656-60; PMID:19923444; http://dx.doi.org/10.4049/jimmunol.0902625
   PubMed Web of Science ®Google Scholar
• Gu T, Kilinc MO, Egilmez NK. Transient activation of tumor-associated T-effectormemory cells promotes tumor eradication via NK-cell recruitment: minimal role for long-term T-cell immunity in cure of metastatic disease. Cancer Immunol, Immunother: CII 2008; 57:997-1005; PMID:18049819; http://dx.doi.org/10.1007/s00262-007-0430-0
   PubMed Web of Science ®Google Scholar
• Watkins SK, Egilmez NK, Suttles J, Stout RD. IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. J Immunol 2007; 178:1357-62; PMID:17237382; http://dx.doi.org/10.4049/jimmunol.178.3.1357
   PubMed Web of Science ®Google Scholar
• Sharma A, Harper CM, Hammer L, Nair RE, Mathiowitz E, Egilmez NK. Characterization of cytokine-encapsulated controlled-release microsphere adjuvants. Cancer Biother Radiopharm 2004; 19:764-9; PMID:15665625; http://dx.doi.org/10.1089/cbr.2004.19.764
   PubMed Web of Science ®Google Scholar
• Slota M, Lim JB, Dang Y, Disis ML. ELISpot for measuring human immune responses to vaccines. Expert Rev Vaccines 2011; 10:299-306; PMID:21434798; http://dx.doi.org/10.1586/erv.10.169
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Ohshita A, Kawabuchi Y, Hihara J, Miyahara E, Noma K, Toge T. Locoregional immunotherapy of malignant ascites from gastric cancer using DTH-oriented doses of the streptococcal preparation OK-432: treatment of Th1 dysfunction in the ascites microenvironment. Int J Oncol 2004; 24:959-66; PMID:15010836
   PubMed Web of Science ®Google Scholar
• Disis ML, Schiffman K, Gooley TA, McNeel DG, Rinn K, Knutson KL. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2neu peptide immunization. Clin Cancer Res 2000; 6:1347-50; PMID:10778962
   PubMed Web of Science ®Google Scholar
• Strome SE, Voss S, Wilcox R, Wakefield TL, Tamada K, Flies D, Chapoval A, Lu J, Kasperbauer JL, Padley D et al. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Res 2002; 62:1884-9; PMID:11912169
   PubMed Web of Science ®Google Scholar
• Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, Tanner JE, Sayers TJ, Seki N, Okumura K, Yagita H et al. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 2004; 199:437-48; PMID:14769851; http://dx.doi.org/10.1084/jem.20031457
   PubMed Web of Science ®Google Scholar
• Egilmez NK, Kilinc MO. Tumor-resident CD8+ T-cell: the critical catalyst in IL-12-mediated reversal of tumor immune suppression. Arch Immunol Ther Exp (Warsz) 2010; 58:399-405; PMID:20872283; http://dx.doi.org/10.1007/s00005-010-0097-7
   PubMed Web of Science ®Google Scholar
• Bajetta E, Del Vecchio M, Mortarini R, Nadeau R, Rakhit A, Rimassa L, Fowst C, Borri A, Anichini A, Parmiani G. Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin Cancer Res 1998; 4:75-85; PMID:9516955
   PubMed Web of Science ®Google Scholar
• Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, Clancy M, Atkins MB. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 2000; 6:1678-92; PMID:10815886
   PubMed Web of Science ®Google Scholar
• Rodriguez-Galan MC, Reynolds D, Correa SG, Iribarren P, Watanabe M, Young HA. Coexpression of IL-18 strongly attenuates IL-12-induced systemic toxicity through a rapid induction of IL-10 without affecting its antitumor capacity. J Immunol 2009; 183:740-8; PMID:19535628; http://dx.doi.org/10.4049/jimmunol.0804166
   PubMed Web of Science ®Google Scholar
• Portielje JE, Lamers CH, Kruit WH, Sparreboom A, Bolhuis RL, Stoter G, Huber C, Gratama JW. Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses. Clin Cancer Res 2003; 9:76-83; PMID:12538454
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3:133-46; PMID:12563297; http://dx.doi.org/10.1038/nri1001
   PubMed Web of Science ®Google Scholar
• Elliott RL, Head JF, McCoy JL. Comparison of estrogen and progesterone receptor status to lymphocyte immunity against tumor antigens in breast cancer patients. Breast Cancer Res Treat 1994; 30:299-304; PMID:7981448; http://dx.doi.org/10.1007/BF00665971
   PubMed Web of Science ®Google Scholar
• Baxevanis CN, Voutsas IF, Gritzapis AD, Perez SA, Papamichail M. HER-2neu as a target for cancer vaccines. Immunotherapy 2010; 2:213-26; PMID:20635929; http://dx.doi.org/10.2217/imt.09.89
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Hayes DF. Re: predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCOCAP HER2-positivity criteria. J Natl Cancer Inst 2012; 104:957-8; PMID:22581974; http://dx.doi.org/10.1093/jnci/djs243
   PubMedGoogle Scholar
• Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13:4429-34; PMID:17671126; http://dx.doi.org/10.1158/1078-0432.CCR-06-3045
   PubMed Web of Science ®Google Scholar